Compare Lumen Technologies Inc (LUMN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs GeneDx Holdings Corp — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Lumen Technologies Inc is far larger — about 2.8× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and GeneDx Holdings Corp for 19 Days on average.
| LUMN | WGS | |
|---|---|---|
Market Cap | $5.73B | $2.02B |
Volume | 17,079,799 | 734,640 |
Sector | Media | Health |
52-Week High | $11.83 | $167.51 |
52-Week Low | $5.53 | $34.51 |
Typical Hold Time | 40 Days | 19 Days |
Enterprise Value | $17.35B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.56, down 5.92% on the day, reflecting ongoing investor caution amid weak profitability and high debt. The stock shows a bearish technical trend with key support at $5.00, while fundamentals reveal declining revenue, negative net income margins, and a challenging turnaround effort. Recent news highlights a Nasdaq listing move and AI-focused networking initiatives, but legacy telecom declines persist.
Outlook remains speculative with high execution risk; the company's deep value (P/S 0.47) and AI growth potential contrast with consistent losses and substantial leverage. Analyst consensus is Reduce, with 60.7% Hold ratings, signaling limited near-term confidence despite strategic pivots.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
